Immune Checkpoint Inhibitors

Global Market Trajectory & Analytics

MCP12532

EXECUTIVE ENGAGEMENTS

OUTREACH

5367
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

859
Interactions with Platform & by Email

PARTICIPANTS

161
Unique # Participated

VALIDATIONS

33
Responses Validated*

COMPETITORS

42
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

74

PAGES

146

EDITION

8

PRICE

USD $4950


  

HIGHLIGHTS

Amid the COVID-19 crisis, the global market for Immune Checkpoint Inhibitors estimated at US$14.6 Billion in the year 2020, is projected to reach a revised size of US$50.7 Billion by 2027, growing at a CAGR of 19.4% over the analysis period 2020-2027. CLTA-4 Inhibitors, one of the segments analyzed in the report, is projected to record a 19.7% CAGR and reach US$10.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PD-1 segment is readjusted to a revised 18.5% CAGR for the next 7-year period.
The Immune Checkpoint Inhibitors market in the U.S. is estimated at US$4.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.4 Billion by the year 2027 trailing a CAGR of 16.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.6% and 17.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.
In the global PD-L1 Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 22.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.7 Billion in the year 2020 will reach a projected size of US$7.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.4 Billion by the year 2027.

SELECT PLAYERS

AstraZeneca PLC; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche AG; Fortress Biotech, Inc.; Immutep Ltd.; Merck & Co., Inc.; Merck KGaA; Novartis International AG; Pfizer, Inc.

SEGMENTS

» Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, Other Applications) » Drug Class (CLTA-4 Inhibitors, PD-1, PD-L1 Inhibitors)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
World Current & Future Analysis for CLTA-4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for CLTA-4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for PD-1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for PD-1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Bladder cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Bladder cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Hodgkin lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Hodgkin lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
USA Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
CANADA
Canada Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
Canada Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
JAPAN
Japan Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
Japan Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
CHINA
China Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
China Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
EUROPE
Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
FRANCE
France Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
France Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
GERMANY
Germany Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
Germany Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
ITALY
Italy Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
Italy Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
UK Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
Rest of Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
Asia-Pacific Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
Rest of World Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
Total Companies Profiled: 42

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com